Endothelial function predicts 5-year adverse outcome in patients hospitalized in an emergency department chest pain unit

Michael Shechter, Sharon Shalom Natanzon, Amir Lerman, Herold Cohn, Megha Prasad, Orly Goitein, Ronen Goldkorn, Michael Naroditsky, Nira Koren-Morag, Shlomi Matetzky

Research output: Contribution to journalArticlepeer-review

Abstract

BackgroundAlthough endothelial function is a marker for cardiovascular risk, endothelial dysfunction assessment is not routinely used in daily clinical practice. A growing challenge has emerged in identifying patients prone to cardiovascular events. We aim to investigate whether abnormal endothelial function may be associated with adverse 5-year outcomes in patients presenting to a chest pain unit (CPU).MethodsFollowing endothelial function testing using EndoPAT 2000 in 300 consecutive patients without a history of coronary artery disease, patients underwent coronary computerized tomographic angiography (CCTA) or single-photon emission computed tomography according to availability.ResultsMean 10-year Framingham risk score (FRS) was 6.6 ± 5.9%; mean 10-year atherosclerotic cardiovascular disease (ASCVD) risk was 7.1 ± 7.2%; median reactive hyperemia index (RHI) as a measure of an endothelial function 2.0 and mean was 2.0 ± 0.4. During a 5-year follow-up, the 30 patients who developed major adverse cardiovascular events (MACE), including all-cause mortality, nonfatal myocardial infarction, hospitalization for heart failure or angina pectoris, stroke, coronary artery bypass grafting, and percutaneous coronary interventions, had higher 10-year FRS (9.6 ± 7.8 vs. 6.3 ± 5.6%; P = 0.032), higher 10-year ASCVD risk (10.4 ± 9.2 vs. 6.7 ± 6.9%; P = 0.042), lower baseline RHI (1.6 ± 0.5 vs. 2.1 ± 0.4; P < 0.001) and a greater degree of coronary atherosclerotic lesions (53 vs. 3%, P < 0.001) on CCTA compared with patients without MACE. Multivariate analysis demonstrated that RHI below the median was an independent predictor of 5-year MACE (odds ratio 5.567, 95% confidence interval 1.955-15.853; P = 0.001).ConclusionOur findings suggest that noninvasive endothelial function testing may contribute to clinical efficacy in triaging patients in the CPU and in predicting 5-year MACE.Clinical Trials.gov IdentifierNCT01618123.

Original languageEnglish (US)
Pages (from-to)729-736
Number of pages8
JournalJournal of Cardiovascular Medicine
Volume24
Issue number10
DOIs
StatePublished - Oct 1 2023

Keywords

  • cardiovascular events
  • chest pain unit
  • EndoPAT
  • endothelial function

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this